AUTHOR INDEX

Acquarini, E., 326
Agid, O., 57
Ahearn, E.P., 196
Akdemir, A., 161
Akiskal, H.S., 375
Albert, U., 456
Alpert, J.E., 488
Altshuler, L., 190
Andresen, B., 213
Andreyka, K., 448
Apter, A., 70, 223
Araya, S., 301
Arzi, R., 223
Assessment Research Group in Schizophrenia (NEDES), 301

Baba, K., 403
Barak, Y., 508
Bauer, M.S., 190
Becker, D.F., 364
Benazzi, F., 139, 461
Beratis, S., 393
Billick, S.B., 202
Blais, M.A., 466
Bleichmar, J., 144
Bloch, M., 57
Boget, T., 64
Bogetto, F., 456
Böthern, A., 213
Botticello, A.L., 410
Bottonari, K., 488
Bowie, C., 306
Breteler, M.H.M., 424, 433
Brody, J.L., 351
Brookner, F., 319
Brown, J., 16
Bruni-Solhkhah, M., 202
Buckley, P.F., 39
Burgert, W., III., 202
Busquets, E., 301

Cadoret, R.J., 272
Calderon, R., 228
Carroll, B.J., 196
Carter, D., 1
Cassidy, F., 196
Catalán, R., 64
Cerny, C., 39
Chambless, D.L., 76
Cohen, B.N., 118
Cohen, P., 16
Collaborative Research Group on Medical Student Health Care, 1
Compton, W.M., III, 111
Cottler, L.B., 111
Crilo, C.M., 283
Crow, S.J., 448

Dag, I., 161
Dannon, N., 477
Davidson, J., 494
Davis, K.L., 306
Delespaul, P., 504
Demirergi, N., 161
Di Ceglie, A., 326
Dolan, R., 441
Donati, D., 326
Donini, M., 326
Dornelas, E.A., 410
du Toit, P.L., 247, 291
Dyck, I., 441

Edelist, D., 223
Edell, W.S., 364
Ehmann, T.S., 32
Eisen, J., 441
Eisen, J.L., 494
Eisler, R.M., 24
Erni, T., 51
Even, D.H., 223

Fava, M., 488
Fehon, D.C., 283
Fenton, B.T., 87
Ferrero, F.P., 382
Fischer, E.H., 410
Fossati, A., 326
Foster, P.S., 24
Frank, E., 1
Frankenburg, F.R., 144, 369
Frare, F., 375
Friedman, J., 306
Friedman, L., 39

Ganzini, L., 1
Gastó, C., 64
Geppert, C.M.A., 351
Germeys, I., 504
Giedd, J.N., 319
Glick, H., 190
Gochman, P., 319
Goethe, J.W., 410
Goodman, L.A., 263
Gost, A., 301
Gothelf, D., 70
Goto, M., 132, 337
Gourzis, P., 393
Graffi, H., 70
Graven, S., 504
Grilo, C.M., 364
Grunhaus, L., 477
Gur, E., 57

Halmi, K.A., 448
Hanin, B., 57
Harrigan, S.M., 498
Harvey, P.D., 306
Hasan, S., 39
Hayashi, N., 240
Hilsenroth, M.J., 466
Hintikka, J., 234
Hirano, S., 337
Holdwick, D.J., Jr., 466
Holliday, S.G., 32
Honkalampi, K., 234
Horesh, N., 70, 223

Iancu, I., 477
Igarashi, Y., 240
Ikegami, N., 403

Järvelin, M.-R., 471
Johnson, J.G., 16
Jokelainen, J., 471
Joukamaa, M., 471

Kan, C.C., 424, 433
Kaplan, R., 342
Karvonen, J.T., 471
Katrivanou, A., 393
Kawashima, Y., 132
Kazamatsuri, H., 240
Keitner, G.I., 96
Keller, M.B., 441
Kelley, J.M., 466
Kelley, L., 196
Khera, G.S., 144
Kilzieh, N., 314
Kimhi, R., 508
Kimura, M., 217
Kinosian, B., 190
Klimidis, S., 416
Kohn, Y., 57
Kokkonen, P., 471
Krausz, M., 213
Kruse, J., 166
Kumra, S., 319
Kusunoki, K., 337

Lambert, M., 213
Langbehn, D.R., 272
Läsky, K., 471
Lavorato, D.H., 124
Lehtonen, J., 234
Lenane, M., 319
Lepkifker, E.,70, 477
Lerer, B., 57
Lipschitz, D.S., 283
Lydiard, R.B., 494
Lyketsos, C., 1

MacEwan, G.W., 32
Maffei, C., 326
Maina, G., 456
Manicavasagar, V., 342
Marcelis, M., 504
Márquez, M., 301
Mata, B., 375
Mathews, C.A., 257
Mattia, J.I., 175

McDermut, W., 96
McGlashan, T.H., 364
McGorry, P.D., 498
McGurk, S.R., 306
Merikangas, R., 87
Merlo, M.C.G., 382
Metzger, D.S., 263
Meuser, K.T., 263
Miller, I.W., 96
Minas, I.H., 416
Mitchell, J.E., 448
Modai, I., 151
Modestin, J., 51
Mojtabai, R., 206
Moriarty, P.J., 306
Mortiz, S., 213
Murata, Y., 217

Naber, D., 213
Narita, T., 337
Nechamkin, Y., 151
Neihaus, D., 291
Nicolson, R., 319
Niehaus, D.J.H., 247
Nierenberg, A.A., 488
Ninan, P., 494
Nishith, P., 111
Novella, L., 326

Ochoa, S., 301
Oldham, J.M., 16
Ono, U., 403
Örsel, S.D., 161
Osher, F.C., 263
Özbay, M.H., 161

Paris, J., 482
Parrella, M.J., 306
Patten, S.B., 124
Penadés, R., 64
Perugi, G., 375
Petersen, T., 488
Peterson, C.B., 448
Phillips, K.A., 494
Piggott, T., 494
Polak, M.A., 42
Ponizovsky, A., 151
Poreh, A., 477
Poustka, F., 223
Preisig, M., 87
Price, L.H., 494

Rapoport, J., 319
Raskind, M., 314
Rasmussen, S.A., 494
Ravizzi, L., 456
Reus, V.I., 257
Ritsner, M., 57, 151
Roberts, L.W., 1, 351
Roboinson, R.G., 217
Rosenberg, S.D., 263
Ryan, C.E., 96

Sakado, K., 337
Salamero, M., 64
Sato, T., 337
Schmitz, N., 166
Schwartz, R.C., 118
Serper, M.R., 306
Shapira, B., 57
Sher, L., 105
Shimoda, K., 217
Siedenburg, E., 202
Simon, A.E., 382
Sirota, P., 508
Skodol, A.E., 16
Slor, H., 508
Smailes, E.M., 16
Smith, G.N., 32
Solomon, D., 96
Someya, T., 132
Sonderegger, P., 51
Spechler, L., 319
Stein, D.J., 247, 291
Steketee, G., 76
Stevens, D.E., 87
Stout, R.L., 441
Sunday, S.R., 448

Tandon, R., 314
Tapp, A., 314
Taskai, S-i., 132
Thaker, G.K., 319
Thompson, K.N., 498
Toni, C., 375
Tran, G.Q., 76
Tress, W., 166
Troudart, T., 57
Trumbetta, S.L., 263
Türkçapar, M.H., 161
Tyano, S., 223

Uehara, T., 132, 337
Usall, J., 301

Vadhan, N., 306
van der Ven, A.H.G.S., 424, 433
van der Zwaard, R., 42
van Kradenburg, J., 247, 291
van Os, J., 504
Varley, C.K., 228
Varley, P., 228
Veijola, J., 471
Venturello, S., 456
Vidaver, R.M., 263
Viinamäki, H., 234
Vincent, J., 228
Vojta, C., 190

Warner, T.D., 1
Weisler, R.H., 196
White, L., 306
Wood, A.E., 314
Wudarsky, M., 319

Yamamoto, K., 416
Yamashina, M., 240
Yamauchi, K., 403

Zalsman, G., 223
Zanarini, M.C., 144, 369
Zimmerman, M., 175
Zislin, J., 57
Zitman, F.G., 424, 433
Zweig-Frank, H., 482

SUBJECT INDEX

ABOS, *see* Anorexic Behavior Observation Scale
ABPS, *see* Awareness of Being a Patient Scale
Abuse
  sexual, and false memory syndrome, 342-348
  susbtance, and risk behavior in SMI patients with HIV/AIDS, 264-271
  verbal during childhood, and risk for personality disease in adolescence and adulthood, 16-23
Academic vulnerability, perceptions associated with personal illness, 1-15
ACE inhibitors, association with major depressive syndrome, 127
Activities of Daily Living index, and rating of GAF, 403-409
Addiction Severity Index-Revised, use for cross-validation of Bendep-SRQ, 433-439
ADHD, *see* Attention deficit hyperactivity disorder
ADL, *see* Activities of Daily Living index
Adolescents
  dimensional stability and change in DSM-III-R personality disorder after hospitalization, 364-368
  follow-up study of psychotic disorders in, 319-325
  hospitalized, correlates of community violence exposure in, 283-290

Adolescents (*Continued*)
psychiatrically hospitalized, psychosocial diagnosis, 223-227
Adult antisocial syndrome, and conduct disorder, 272-282
Affective disorders, assortive mating in, 257-262
Affective disorders, studies of assortive mating in, 259
Agoraphobia
comorbidity and outcome, 76-86
and false memory syndrome, 345
reliability of PDSQ screening, 175-189
Agreeableness, determination in MDD using five-factor inventory, 488-493
AID, *see* Automatic Interaction Detector
AL, *see* Alexithymia
Alcohol, fetal exposure and risk for ASPD, 272-282
Alcohol abuse
comorbidity with bipolar disorder, 375-381
concern about academic jeopardy in medical school, 1-15
reliability of PDSQ screening, 175-189
and social phobia-bipolar disorder coexistence, 375-381
Alcoholism
and mood disorders, familial relationship between, 87-95
relationship to anxiety
and bipolar mood disorder, 89
and dysthymia, 89
and major depressive disorder, 89
unipolar mood disorders secondary to, 87-95
Alexithymia
and depression in a general population, 234-239
prevalence and sociodemographic correlates in young adult population, 471-476
and suicidality in panic disorder, 477-481
Anger-hostility, SCL-90-R mean scores, 169
Anorexia nervosa
co-morbidity with OCD, 456-460
diagnostic criteria, 448-455
Anorexic Behavior Observation Scale, study of psychoeducation in families of patients with eating disorders and expressed emotion, 132-138
Anosognosia, 498
Antihyperlipidemic medication, association with major depressive syndrome, 127
Antipsychotic medication, and depression in schizophrenia, 314-318
Antisocial personality disorder, adult
and conduct disorder, 272-282
adult, DSM-III criteria, 274
Antisocial syndrome, adult, and adult ASPD, 277
Anxiety
relationship to
alcoholism and mood disorders, 89
suicidal behavior, 73
SCL-90-R mean scores, 169
Anxiety disorders
alexithymia as predictor of suicidality in, 477-481
see also specific names; Generalized anxiety disorder; Major depressive disorder
ASI-R, *see* Addicition Severity Index-Revised
ASPD, *see* Antisocial personality disorder
Assortive mating, in affective disorders, 257-262
other studies of, 259
Attention deficit hyperactivity disorder
childhood, retrospective assessment in adults using Italian version of WURS, 326-336
prognostic significance of psychotic phenomena in children with, 319-325
tics in children treated with stimulants, 228-233
Attitude, patient, improved in schizophrenia, 240-246
Automatic Interaction Detector, and rating of GAF, 403-409
Awareness of Being a Patient Scale, assessment of psychotic symptoms in schizophrenia, 242, 244
Axis II disorders
co-occurrence in DSM-II-R and DSM-IV, 452
diagnoses in DSM-III-R and DSM-IV, 451

BABS, *see* Brown Assessment of Beliefs Scale
BDI, *see* Beck Depression Inventory
Beck Depression Inventory, and alexithymia and depression in a general population, 234-239
Bendep-SRQ, *see* Benzodiazepine Dependence Self-Report Questionnaire
Benefit-related issues, ethics of in psychiatric research, 353-354
Benzodiazepine, determining severity of dependence, 424-432, 433-439
Benzodiazepine Dependence Self-Report Questionnaire
cross-validation of, 433-439
standardization, 424-432
Beta blockers, association with major depressive syndrome, 127
Bipolar disorder
assortive mating in, 259
quality of life across mood states in, 190-195
Bipolar II disorder
comorbidity with social phobia, 375-381
diagnosis, sensitivity and specificity of clinical markers, 461-465
Bipolar mood disorder, relationship to anxiety and alcohol disorders, 89
BN, *see* Bulimia nervosa
Bonn Scale for the Assessment of Basic Symptoms, study of early signs and symptoms of psychosis, 384-386
Borderline personality disorder
follow-up study, 482-487
high rates of mental health services used by patients with, 144-150
related to childhood verbal abuse, 19-22
treatment histories of patients with, 144-150
BPD, *see* Borderline personality disorder
BPRS, *see* Brief Psychiatric Rating Scale
Brief Psyschiatric Rating Scale, and rating of GAF, 403-409
Brown Assessment of Beliefs Scale, assessment of OCD, 494-497
BSABS, *see* Bonn Scale for the Assessment of Basic Symptoms
Bulimia, reliability of PDSQ screening, 175-189
Bulimia nervosa
diagnostic criteria, 448-455
with and without OCD syndromes, 456-460
BZD, *see* Benzodiazepine

Calcium channel blockers, association with major depressive syndrome, 124-131

Cardiovascular medication, association with major depressive syndrome, 127
Carroll Depression Scale, and self-rating of mood in depressed, manic, and normal subjects, 196-201
CART, *see* Classification and Regression Tree
Case illustration, ethical questions in psychiatric research, 358-360
Case study, early stages of psychosis, 387-388
CDS, *see* Carroll Depression Scale
Childhood, verbal abuse during and risk for personality disease in adolescence and adulthood, 16-23
Childhood sexual abuse, and false memory syndrome, 342-348
Children
  follow-up study of psychotic disorders in, 319-325
  multidimensionally impaired, 319
CIDI, *see* Composite International Diagnostic Interview
Classification and Regression Tree, and rating of GAF, 403-409
Clinical markers, diagnosis of bipolar II disorder, sensitivity and specificity of, 461-465
Clomipramine, treatment, OCD, 27
Cognition, impairment in schizophrenia and neuropsychological tests, 306-313
Cognitive dysfunction, subjective, in first-episode and chronic schizophrenia patients, 213-216
Communication, personal feelings, relationship of lack of to suicidal behavior, 70-75
Comorbidity
  agoraphobia, 78-86
    and false memory syndrome, 345
  alcohol abuse
    in bipolar disorder, 375-381
    and social phobia, 375-381
  anorexia nervosa, and OCD, 456-460
  antisocial personality disorder and conduct disorder, 272-282
  axis I and II, OCD and agoraphobia, 76-86
  bulimia nervosa and OCD, 456-460
  eating disorders and bulimia nervosa, 456-460
  OCD and putative OCSD, 294
  panic disorder/agoraphobia with
    bipolar disorder, 375-381
    unipolar disorder, 375-381
Composite International Diagnostic Interview, use and reliability in longitudinal study, 369-374
Conduct disorder, and adult antisocial syndrome, 272-282
Confidentiality
  issues, ethics of in psychiatric research, 354
  from medical school, and medical insurance, 7-8
Conscientiousness, determination in MDD using five-factor inventory, 488-493
Corticosteroids, association with major depressive syndrome, 124-131
CSA, *see* Childhood sexual abuse

Data presentation issues, ethics of in psychiatric research, 356
Decision pathway, initial phases of psychosis, 387
Decisional capacity issues, ethics of in psychiatric research, 354-355
Demographic Psychosocial Inventory, stress and gender, 156
Demography
  alexithymia in young adults, 471-476
  DSM-IV axis I diagnoses, 328
Demography (*Continued*)
  DSM-IV diagnoses, 181
  major depression, 209
  OCD patients with and without cormorbid putative OCSD, 294
  smoking status in schizophrenic patients, 394
  social phobic patients with bipolar or unipolar disorder, 377
Depressed patients, self-rated mood in, 196-201
Depression
  alexithymia as predictor of suicidality in, 477-481
  and alexithymia, in a general population, 234-239
  assessment with Turkish version of HDRS, 161-165
  assortive mating in, 259
  bipolar II disorder, sensitivity and specificity of clinical markers, 461-465
  during acute psychotic episode in schizophrenia, 314-318
  effect on quality of life in bipolar disorder, 190-195
  family function and suicide in, 96-104
  major
    factor validity of Temperament and Character Inventory, 337-341
    impairment in, 206-212
  relationship to
    antipsychotic medication in schizophrenia, 314-318
    suicidal behavior, 73
  SCL-90-R mean scores, 169
  and suicidal intent in schizophrenia patients, 118-123
  see also Major depressive disorder; specific disorders
Depressive mixed states, in depressed outpatients, 139-143
Dextroamphetamine, development of tics in ADHD children treated with, 228-233
Diagnosis
  bipolar II disorder, sensitivity and specificity of clinical markers, 461-465
  eating disorders, differences in DSM-III-R and DSM-IV, 448-455
  hysterical psychosis, reactive/psychogenic psychosis, and schizophrenia, 51-56
  implications of impairment in depression, 206-212
  see also specific test names
Diagnostic Interview for Borderlines, Revised, follow-up study of BPD, 482-487
Diagnostic Interview for Personality Disorders, use and reliability in longitudinal study, 369-374
Diagnostic Interview Schedule, use and reliability in longitudinal study, 369-374
DIB-R, *see* Diagnostic Interview for Borderlines, Revised
Digoxin, association with major depressive syndrome, 127
DIPD, *see* Diagnostic Interview for Personality Disorders
Disability Assessment Scale, use to measure gender differences in schizophrenia outpatients, 301-305
Disruptive behavior disorders, prognostic significance of psychotic phenomena in children with, 319-325
Dissociation
  characteristics, 46
  differentiation from pseudohallucinations, 46-47
Dissociative disorders, *see* Obsessive-compulsive spectrum disorders
Dissociative phenomena, differentiation from pseudohallucinations, 46-47
Diuretics, association with major depressive syndrome, 127

Dopamine, role in SAD, 107-108
DPSI, *see* Demographic Psychosocial Inventory
Drug abuse
  concern about academic jeopardy in medical school, 1-15
  reliability of PDSQ screening, 175-189
Drug abusers, gender differences in risk factors for trauma and PTSD, 111-117
Drug use
  after witnessing community violence, 283-290
  and age of onset of trauma, 115
DSM-III-R personality disorder
  dimensional stability and change in adolescents after hospitalization, 364-368
  reliability of axis I and II disorders over course of longitudinal study, 369-374
DSM-IV axis I disorders, reliability of PDSQ screening, 175-189
DSM-IV personality disorder criteria sets, perceived clarity and understandability, 466-470
Dysthymia, relationship to anxiety and alcohol disorders, 89

Eating Disorder Evaluation Scales, study of psychoeducation in families of patients with eating disorders and expressed emotion, 132-138
Eating disorders
  differences in DSM-III-R and DSM-IV diagnoses, 448-455
  psychoeducation for families of patients with, 132-138
  see also Anorexia nervosa; Bulimia nervosa; Obsessive-compulsive spectrum disorders
EDES, *see* Eating Disorder Evaluation Scales
EE, *see* Expressed emotion
Efforts to Reduce the Spread of AIDS sample, study of gender differences in risk factors for PTSD in drug abusers, 111-117
Elderly, *see* Geriatric patients
Emotion
  high expressed, and family function, 504-507
  see also Alexithymia
Environment, adverse, and risk for ASPD, 272-282
Epidemiology, alexithymia in young adults, 471-476
ERSA, *see* Efforts to Reduce the Spread of AIDS sample
Ethical questions, case illustrations in psychiatric research, 358-360
Ethics
  of psychiatric research protocols, 351-363
  research, resources, 361-362
Evaluation jeopardy, and health care issues in medical school, 8-9
Exclusion issues, ethics of in psychiatric research, 354
Expressed emotion
  high, and family function, 504-507
psychoeducation for families of patients with, 132-138
Extraversion, determination of in MDD using five-factor inventory, 488-493

FACES, *see* Family Adaptability and Cohesion Evaluation Scales
FAD, *see* Family Assessment Device
False memory syndrome
  and childhood sexual abuse, 342-348
  existence of, 342-348
Family Adaptability and Cohesion Evaluation Scales, study of psychoeducation in families of patients with eating disorders and expressed emotion, 132-138
Family Assessment Device, testing of family function in depressed adults, 97, 99, 100
Family function
  and high expressed emotion, 504-507
  and suicide in depressed adults, 96-104
Family studies, association between alcoholism and mood disorders, 88-89
FARS, assessment of biopsychosocial symptomatology in schizophrenic patients, 119-110
FCQ, *see* Frankfurt Complaint Questionnaire
Fetal alcohol exposure, and risk for ASPD, 272-282
FFI, *see* Five-Factor Inventory
First-episode psychosis, patient awarenss of illnes in, 498-503
Five-Factor Inventory, characterization of MDD, 488-493
Five-Minute Speech Sample
  determination of family expressed emotion level, 504-507
  study of psychoeducation in families of patients with eating disorders and expressed emotion, 132-138
Fluoxetine, treatment, OCD, 27
Fluvoxamine, treatment, OCD, 27
FMS, *see* False memory syndrome
FMSS, *see* Five-Minute Speech Sample
Frankfurt Complaint Questionnaire, assessment of cognitive dysfunction in schizophrenia, 213-216
Frequency of Illness Scale, comparison of Impact of Illness Scale with, 420

GAD, *see* Generalized anxiety disorder
GAF, *see* Global Assessment of Functioning Scale
Gender
  and association of medication with major depressive syndrome, 124-131
  differences in
    risk factors for trauma and PTSD in drug abusers, 111-117
    schizophrenic outpatients sample, 301-305
  and hair-pulling characteristics, 247-256
  and health care concerns in medical students, 11
  and libido before and after stroke, 217-222
  as moderator of stress-distress relation, 155-156
  and perception of risk factors, 151-160
  and psychosocial risk factors for psychological distress among immigrants, 151-160
  and risk for ASPD, 272-282
  and sexual dysfunction following stroke, 217-222
  and suicidal intent in schizophrenia patients, 118-123
General Health Questionnaire
  high false-positive rate in identifying mental disorders, 170-171
  and improvement of screening of mental disorders, 166-173
Generalized anxiety disorder
  reliability of PDSQ screening, 175-189
  and social functioning after panic disorder remission, 441-447
Genetic diseases, and psychosis, Werner's syndrome, 508-510
Geriatric patients, validation of MAT with MMSE in, 202-205
GHQ, comparison of Impact of Illness Scale with, 420
GHQ-12, *see* General Health Questionnaire

Global Assessment of Functioning Scale
assessement of function in schizophrenic patients, 119-110
follow-up study of BPD, 482-487
rating process, 403-409
study of psychoeducation in families of patients with eating disorders and expressed emotion, 132-138
use to measure gender differences in schizophrenia outpatients, 301-305

Hair-pulling
characterstics and phenomenology, 247-256
comorbid behaviors, 253-254
Hallucinations
discrimination from pseudohallucinationa, 43-44
see also Pseudohallucinations
HAM-D, *see* Hamilton Rating Scale for Depression
Hamilton Depression Rating Scale
assessment of insight in schizophrenia, 39-41
determination of alexithymia as predictor of suicidality in AD, 477-481
scores in schizophrenia before and after antipsychotic medication, 3116
and sexual dysfunction following stroke, 217-222
Turkish version, reliability and validity, 161-165
HDRS, *see* Hamilton Depression Rating Scale
Health Belief Model, risk behavior in HIV infection, 264
Health care
preference for obtaining outside training institution, 6-7
stigmatizing issues regarding in medical school, 5-6
Health problems, and evaluation jeopardy in medical school, 8-9
Histamine blockers, association with major depressive syndrome, 128
Hopelessness, relationship to suicidal behavior, 73
Hopkins Symptom Check List, prevalence and sociodemographic correlates of alexithymia in young adults, 471-476
Hospitalization
adolescents, assessment of dimensional stability and change in DSM-III-R personality disorder, 364-368
psychiatric patients
brief measure of post-hospital adjustment, 410-415
and exposure to community violence, 283-290
HSCL-25, *see* Hopkins Symptom Check List
5-HT2A-1438G/A gene promoter polymorphisms, and seasonality in SAD, 105-110
5-HTTLPR gene promoter polymorphisms, and seasonality in SAD, 105-110
Human immunodeficiency virus infection, models of risk behavior, 264
Human immunodeficiency virus/acquired immunodeficiency syndrome, risk behavior in SMI patients with, 263-271
Hypnotherapy, and false memory syndrome, 344-345
Hypochondriasis, reliability of PDSQ screening, 175-189
Hypomanic symptoms, in depressed outpatients, 139-143
Hysterical psychosis
comparison with reactive/psychogenic psychosis and schizophrenia, 51-56
follow-up study, 51-56

IADL, *see* Instrumental Activities of Daily Living Scale
IIS, *see* Impact of Illness Scale
Illness
determining psychosocial impact, 416-423
personal, associated with perceptions of academic vulnerability, 1-15
reduced patient awareness of in first-episode psychosis, 498-503
Illness impact scale, reliability, validity, and cross-cultural utility, 416-423
Imagery
characteristics, 45
discrimination from pseudohallucinations, 45-47
factors in specification process, 48
IMB model, risk behavior in HIV infection, 264
Immigrants, risk factors for psychological distress and gender, 151-160
Impact of Illness Scale
correlation with other measures, 420
reliability, validity, and cross-cultural utility, 416-423
test questions, 422
Impulse-control disorders, *see also* Obsessive-compulsive spectrum disorders
Incentive issues, ethics of in psychiatric research, 355-356
Informed consent, ethics of in psychiatric research, 354-355
Injurious behavior, and hair-pulling, 254
Inpatients, BPD, treatment histories, 144-150
Insight
lack of in schizophrenia, 39-41
in OCD, role in predicting treatment outcome, 494-497
Institutional issues, ethics of in psychiatric research, 356
Instrument for the Retrospective Assessment of Schizophrenia, study of early signs and symptoms of psychosis, 384-386
Instrumental Activities of Daily Living Scale, comparison of Impact of Illness Scale with, 420
Insurance, medical, and confidentiality from medical school, 7-8
Internal State Scale, self-reporting of mood state in bipolar disorder patients, 190-195
Interpersonal sensitivity, SCL-90-R mean scores, 169
IRAOS, *see* Instrument for the Retrospective Assessment of Schizophrenia
ISS, *see* Internal State Scale

Jourad's Self-Disclosure Questionnaire, measurement of self-disclosure as related to suicidal behavior, 70-75
JSDQ, *see* Jourad's Self-Disclosure Questionnaire

Latent trait standardization, and Bendep-SRQ, 424-432
Libido, before and after stroke, 217-222
Life events, negative
increased prevalence in subtypes of major depressive disorder, 57-63
list of, 62
LIFE-UP, *see* Longitudinal Interval Follow-Up Evaluation-Upjohn
Longitudinal Interval Follow-Up Evaluation-Upjohn, determination of social functioning after panic disorder remission, 441-447
Longitudinal study, reliability of axis I and II personality disorders over course of, 369-374

Major depression
factor validity of Temperament and Character Inventory, 337-341
impairment in, 206-212
self-rated impairment and sociodemographic and illness characteristics, 209
Major depressive disorder
clarity of DSM-IV criteria for, 466-470
effect of by dependent measure, 444
increased prevalence of negative life events in subtypes of, 57-63
relationship to anxiety and alcohol disorders, 89
reliability of PDSQ screening, 175-189
and social functioning after panic disorder remission, 441-447
use of five-factor personality inventory, 488-493
Major depressive syndrome
association of with medication and gender, 124-131
and medication use, 124-131
Management for the Assessment and Documentation of Psychopathology, assessment of insight in schizophrenia, 39-41
Manic patients, self-rated mood in, 196-201
MAT, *see* Mental Alternation Test
Mating, assortive, in affective disorders, 257-262
Maudsley Personality Inventory, assessment of patient attitude in schizophrenia, 240-246
McMaster Clinical Rating Scale, testing of family functioning in depressed adults, 97, 101
MCRS, *see* McMaster Clinical Rating Scale
MDD, *see* Major depressive disorder
MDD, *see* Major depressive disorder
MDI, *see* Multidimensionally impaired
Medical school
preference for obtaining health care outside the institution, 6-7
health concerns of students, 10-13
perceptions of academic vulnerability associated with personal illness, 1-15
policy and curricular implications of personal health issues, 13
stigmatizing health-related issues in, 5-6
Medication
antipsychotic, and depression in schizophrenia, 314-318
and major depressive syndrome side effect, 124-131
see also specific drug names
Melatonin, role in SAD, 107-108
Memory, false, existence of syndrome, 342-348
Mental Alternation Test, validation with Mini-Mental State Examination in geriatric patients, 202-205
Mental disorders, improvement of screening using GHQ-12 and SCL-90-R subscales, 166-173
Mental health, and concerns in medical students, 10-13
Mental illness
severe, risk behavior in HIV/AIDS patients with, 263-271
symptoms in medical school students, 1-15
Methylphenidate, development of tics in ADHD children treated with, 228-233
Mini-Mental State Examination, validation of MAT with in geriatric patients, 202-205
Mitofsky-Waksberg random digit dialing, selection of community sample for study of medication use and major depressive syndrome, 124-131
MMSE, *see* Mini-Mental State Examination
Mood
states, bipolar disorder, quality of life across, 190-195
self-rated, in depressed, manic, and normal subjects, 196-201
Mood disorders
and alcoholism, familial relationship between, 87-95
unipolar, as secondary to alcoholism, 87-95
MPI, *see* Maudsley Personality Inventory
Multidimensionally impaired, children, 319
Multiple personality disorder, and false memory syndrome, 346
Multiple Visual Analog Scale, and self-rating of mood in depressed, manic, and normal subjects, 196-201
MVAS, *see* Multiple Visual Analog Scale

Narcissistic personality disorder, related to childhood verbal abuse, 19-22
Negative life events, increased prevalence in subtypes of major depressive disorder, 57-63
Negative life events, list of, 62
Negative schizophrenia, evolution, 64-69
NEO, *see* NEO five-factor inventory
NEO five-factor inventory, characterization of MDD, 488-493
NEO-FFI, *see* NEO five-factor inventory
Neuropsychological tests, and cognitive impairment in schizophrenia, 306-313
Neurotocism, determination of in MDD using five-factor inventory, 488-493
Normal subjects, self-rated mood in, 196-201

OAP, *see* Outcome Assessment Program
Obituary, Arnold Jerome Friedhoff, M.D., 349
Obsessions
characteristics, 45
discrimination from pseudohallucinations, 45-47
Obsessive-compulsive disorder
and bulimia nervosa, 456-460
clinical features compared with comorbid OCSD, 296
cognitive-behavioral treatment, 25-27
comorbidity
with bipolar disorder, 375-381
and outcome, 76-86
with unipolar disorder, 375-381
comparison with obsessisve-compulsive spectrum disorders using structured clinical interview, 291-300
current treatment, 25-27
etiological models, 24-25
and hair-pulling, 254
insight and treatment outcome, 494-497
neurobiological model, 24-25
neurobiological treatment, 27
prediction of response to sertraline in, 494-497
reliability of PDSQ screening, 175-189
SCL-90-R mean scores, 169
treatment, integrative approach, 24-31
Obsessive-compulsive personality disorder, related to childhood verbal abuse, 19-22
Obsessive-compulsive spectrum disorders, comparison using structured clinical interview, 291-300

OCD, *see* Obsessive-compulsive disorder
OCSD, *see* Obsessive-compulsive spectrum disorders
Openness, determination in MDD using five-factor inventory, 488-493
Opiate analgesics, association with major depressive syndrome, 124-131
Oral contraceptives, association with major depressive syndrome, 128
Outcome Assessment Program, brief measure of post-hospital adjustment in psychiatric patients, 410-415
Outpatients, depressed, major depressive episodes with hypomanic symptoms in, 139-143

Pain Score Scale, comparison of Impact of Illness Scale with, 420
Panic disorder
  with agoraphobia, comorbidity and treatment outcome, 76-86
  alexithymia as predictor of suicidal behavior in, 477-481
  course of social functioning after remission, 441-447
  reliability of PDSQ screening, 175-189
Panic disorder/agoraphobia, comorbidity with
  bipolar disorder, 375-381
  unipolar disorder, 375-381
PANSS, *see* Positive and Negative Syndrome Scale
Paranoid ideation, SCL-90-R mean scores, 169
Paranoid personality disorder, related to childhood verbal abuse, 19-22
PD, *see* Panic disorder
PD, *see* Personality disorder
PDA, *see* Panic disorder with agoraphobia
PDE, *see* Personality Disorder Examination
PDSQ, *see* Psychiatric Diagnostic Screening Questionnaire
Peer review issues, ethics of in psychiatric research, 356
Pemoline, development of tics in ADHD children treated with, 228-233
Perception, factors in specification process of, 48
Personal History of Depressive Disorders, determination of social functioning after panic disorder remission, 441-447
Personality disorder criteria sets, DSM-IV, perceived clarity and understandability, 466-470
Personality Disorder Examination
  assessment of adolescent patients after hospitalization, 364-368
  use and reliability in longitudinal study, 369-374
Personality Disorder Interview, use and reliability in longitudinal study, 369-374
Personality disorder
  DSM-III-R, dimensional stability and change in adolescents after hospitalization, 364-368
  DSM-IV axis I diagnoses, reliability using Italian version of WURS, 328
  related to childhood verbal abuse, 19-22
Personality structure, underlying, use of TCI to determine in patients with major depression, 337-341
Phenotype, assortive mating in affective disorders, 257-262
Phobic anxiety, SCL-90-R mean scores, 169
Physical Illness Checklist Scale, comparison of Impact of Illness Scale with, 420
PICL, *see* Physical Illness Checklist Scale
POMS, *see* Profile of Mood States
Positive and Negative Syndrome Scale
  assessment of
    insight in schizophrenia, 39-41
    psychotic symptoms in schizophrenia, 242-243
  and cognitive impairment in schizophrenia, 306-313
  correlation of factor scores with RAPP factor scores, 35
  items for schizophrenic groups with and without neuropsychological impairment, 67
  use to measure gender differences in schizophrenia outpatients, 301-305
Post-traumatic stress disorder
  after witnessing community violence, 283-290
  characteristics of ERSA subjects by status for, 114
  gender differences in risk factors for in drug abusers, 111-117
  reliability of PDSQ screening, 175-189
Prodromal signs and symptoms, descriptive studies, 384-386
Prodrome concept, early stages of first-episode psychosis, 382-392
Profile of Mood States, study of psychoeducation in families of patients with eating disorders and expressed emotion, 132-138
Progeroid syndromes, *see* Werner's syndrome
Prognosis
  and prevalence of negative life events in major depressive disorder, 57-63
  significance of psychotic phenomena in children with disruptive behavior disorders, 319-325
Pseudohallucinations
  assessment of validity of concept, 42-50
  definition, 42
  differentiation from other psychopathological symptoms, 43-47
  discrimination from hallucinations, 43
  origin of concept, 42-43
Psychiatric research protocols, ethical aspects, 351-363
Psychiatric Diagnostic Screening Questionnaire
  criteria for modification of subscales and items, 177
  development, reliability, and validity, 175-189
Psychiatric research protocols, case illustrations of ethical questions, 358-360
Psychoeducation, families of patients with eating disorders and expressed emotion, 132-138
Psychosis
  decision pathway for initial phases, 387
  descriptive studies of early signs and symptoms, 384-386
  early stages, case study, 387-388
  first-episode
    early stages, 382-392
    reduced patients awareness of illness of in, 498-503
  and genetic diseases, Werner's syndrome, 508-510
  hysterical
    comparison with reactive/psychogenic psychosis and schizophrenia, 51-56
    follow-up study, 51-56
  multidimensional assessment, 32-38
  phenomenological approach to early signs and symptoms, 386
  reactive/psychogenic, follow-up study, 51-56
  reliability of PDSQ screening, 175-189
Psychosocial diagnosis, in psychiatrically hospitalized adolescents, 223-227

Psychosocial stress, gender differences, 151-160
Psychotic disorders, follow-up study of in children and adolescents, 319-325
Psychotic illness, and family expressed emotion, 504-507
Psychoticism, SCL-90-R mean scores, 169
PTSD, *see* Post-traumatic stress disorder
Pyschiatric patients, brief measure of post-hospital adjustment, 410-415
Pyschiatric research protocols, questions to consider regarding ethical accepatability, 357

Quality of life, across mood states in bipolar disorder patients, 190-195

RAPP, *see* Routine Assessment of Patient Progress
Rasch Scaling Model, use for standardization of Bendep-SRQ, 424-432
RDD, *see* Mitofsky-Waksberg random digit dialing
Reactive/psychogenic pscyhosis, follow-up study, 51-56
Recruitment issues, ethics of in psychiatric research, 354
Re-experiences
  characteristics, 46
  differentiation from pseudohallucinations, 46-47
  factors in specification process, 48
Relatives, comorbidity of alcoholism and mood disorders, 87-95
Research Diagnostic Criteria Schedule for Affective Disorders-Lifetime, determination of social functioning after panic disorder remission, 441-447
Research ethics, resources, 361-362
Research team, ethics of in psychiatric research, 352
Risk behavior
  in HIV/AIDS patients with SMI, 263-271
  models of in HIV infection, 264
Risk factors
  psychosocial for pscyhological distress among immigrants, and gender, 151-160
  psychotic phenomena in children with disruptive behavior disorders, 322
Risk-related issues, ethics of in psychiatric research, 353-354
Routine Assessment of Patient Progress
  relationship with other outcome measures, 35-36
  validation of for multidimensional assessment of psychosis, 32-38
  varimax-rotated factor loadings, 34

SAD, *see* Seasonal affective disorder
SCALUP, determination of social functioning after panic disorder remission, 441-447
SCAN, *see* Schedules for Clinical Assessments in Neuropsychiatry
Schedule for DSM-III-R Diagnosis, follow-up study of BPD, 482-487
Schedules for Clinical Assessments in Neuropsychiatry, use for cross-validation of Bendep-SRQ, 433-439
Schizophenia
  correlation matrix of dimensions of insight, 40
  deficit in, relationship between negative symptoms and neurocognition, 64-69
  depression during acute psychotic episode, 314-318
  expressed emotion and patient family function in, 504-507
Schizophenia (*Continued*)
  factors affecting smoking in, 393-402
  first-episode and chronic, subjective cognitive dysfunction in, 213-216
  follow-up study, 51-56
  gender differences in outpatients sample, 301-305
  and gender in suicidal patients, 118-123
  improved patient attitude in, 240-246
  and lack of insight, 39-41
  means of adaptation level variables in groups with and without neuropsychological impairment, 66
  as neurodevelopmental disorder, 213-216
  neuropsychological tests and cognitive impairment in, 306-313
  patient awareness of illness in, 498-503
  relationship of depression to antipsychotic medication, 314-318
  suicidal intent in patients with, 118-123
SCID, *see* Schedule for DSM-III-R Diagnosis
SCID-I, *see* Structured Clinical Interview for Axis I Disorders
SCID-OSCD, *see* Structured Clinical Interview for Obsessive-Compulsive Disorders
Scientific issues, ethics of in psychiatric research, 352
SCL-90, *see* Symptom Checklist-90
SCL-90-R, *see* Symptom Checklist
Screening, mental disorders, improvement using GHQ-12 and SCL-90-R subscales, 166-173
Seasonal affective disorder
  dopamine role in, 107-108
  melatonoin role in, 107-108
  and seasonality, genetic studies, 105-110
  serotonin role in, 107
Seasonality, and seasonal affective disorder, genetic studies, 105-110
Selection issues, ethics of in psychiatric research, 354
Selective serotonin reuptake inhibitors, treatment, OCD, 27
Self-disclosure, relationship to suicidal behavior, 70-75
Serotonin
  reuptake inhibitors, treatment, OCD, 27
  role in SAD, 107
Sertraline, prediction of response to in OCD, 494-497
Severe mental illness, risk behavior in HIV/AIDS patients with, 263-271
Sexual abuse, childhood, and false memory syndrome, 342-348
Sexual dysfunction, following stroke, 217-222
SHRS, *see* Subjective Health Rating Scale
Side effects, major depressive syndrome and specific medications, 124-131
SIDP, *see* Structured Interview for DMS Personality Disorders
SMI, *see* Severe mental illness,
Smoking, factors affecting in schizophrenia, 393-402
Social Adjustment Scale, follow-up study of BPD, 482-487
Social functioning, after panic disorder remission, 441-447
Social functioning, gender differences in schizophrenia outpatients, 301-305
Social phobia
  with bipolar or unipolar disorder
    demography of patients , 377
    symptomatic features, 378
  bipolar II and unipolar comorbidity in, 375-381
  reliability of PDSQ screening, 175-189

Sociodemography, alexithymia in young adults, 471-476
Somatization
  reliability of PDSQ screening, 175-189
  SCL-90-R mean scores, 169
Somatoform disorders, *see also* Obsessive-compulsive spectrum disorders
SP, *see* Social phobia
SRI, *see* Serotonin reuptake inhibitors
SRS, *see* Suicide Risk Scale
SSRI, *see* Selective serotonin reuptake inhibitors
Standardization, Bendep-SRQ, 424-432
Stimulants, tics in ADHD children treated with, 228-233
Stress, pscyhosocial, gender differences, 151-160
Stroke, sexual dysfunction following, 217-222
Structured Clinical Interview, use to determine differences in eating disorder diagnoses, 448-455
Structured Clinical Interview for Axis I Disorders, use and reliability in longitudinal study, 369-374
Structured Clinical Interview for DSM Personality Disorders, use and reliability in longitudinal study, 369-374
Structured Clinical Interview for DSM-III-R, assessment of axis I and II comorbidity on outcome for OCD and agoraphobia, 76-86
Structured Clinical Interview for DSM-IV, sensitivity and specificity of clinical markers for bipolar II disorder, 461-465
Structured Clinical Interview for Obsessive-Compulsive Spectrum Disorders, comparison of obsessive-compulsive disorder with obsessuve-compulsive spectrum disorders, 291-300
Structured Clinical Interview for the DSM-III-R Non-Affective Disorders-Patient's Version, determination of social functioning after panic disorder remission, 441-447
Structured Interview for DMS Personality Disorders, use and reliability in longitudinal study, 369-374
Subjective Health Rating Scale, comparison of Impact of Illness Scale with, 420
Substance abuse
  and dependence, diagnoses in DSM-III-R and DSM-IV, 451
  and risk behavior in SMI patients with HIV/AIDS, 263-271
Suicidal behavior, relationship to self-disclosure, 70-75
Suicidality, alexithymia as predictor of in panic disorder, 477-481
Suicide
  and family function in depressed adults, 96-104
  intent in patients with schizophrenia, 118-123
Suicide Risk Scale, determination of alexithymia as predictor of suicidality in AD, 477-481
Symptom Check List-90, follow-up study of BPD, 482-487
Symptom Checklist, and improvement of screening of mental disorders, 166-173
Symptom Checklist-90, use for cross-validation of Bendep-SRQ, 433-439

TAS, *see* Toronto Alexithymia Scale
TAS-20, *see* Toronto Alexithymia Scale
TCI, *see* Temperament and Character Inventory
Temperament and Character Inventory, factor validity of in patients with major depression, 337-341
Theory or Reasoned Action, risk behavior in HIV infection, 264
Tic disorders, *see also* Obsessive-compulsive spectrum disorders
Tics
  in ADHD children treated with stimulants, 228-233
  and hair-pulling, 254
Toronto Alexithymia Scale, 234-239
  prevalence and sociodemographic correlates of alexithymia in young adults, 471-476
  determination of alexithymia as predictor of suicidality in AD, 477-481
Trauma
  age of onset and drug use, 115
  gender differences in risk factors for in drug abusers, 111-117
Traumatization, and exposure to community violence, 283-290
Treatment histories, patients with BPD, 144-150
Trichotillomania, characteristics and phenomenology, 247-256
TTM, *see* Trichotillomania
Twin studies, seasonality and SAD, 105-110

Unipolar disorder, comorbidity with social phobia, 375-381
Unipolar mood disorders, as secondary to alcoholism, 87-95

Verbal abuse, childhood, and risk for personality disease in adolescence and adulthood, 16-23
Violence
  community, exposure in hospitalized adolescents, 283-290
  potential, after witnessing community violence, 283-290
Voices, internal localization, and discrimination between pseudohallucinations and hallucinations, 44-45

Wender Utah Rating Scale, reliability and validity of Italian version, 326-336
Werner's syndrome, and psychosis, case report, mother and son with, 508-510
Wisconsin Manual, study of early signs and symptoms of psychosis, 384-386
World Health Organization Life Chart from the Multi-Center Study on the Course and Outcome of Schizophrenia, and family expressed emotion, 504-507
World Health Organization Psychiatric Disability Assessment Schedule, and rating of GAF, 403-409
WURS, *see* Wender Utah Rating Scale

Yale-Brown Obsessive-Compulsive Rating Scale, assessment of OCD, 494-497
Y-BOCS, *see* Yale-Brown Obsessive-Compulsive Rating Scale